OCUGEN INC. - COMMON

0,9222

25-ноября-24 15:45:01

15 мин. задержка

Акции

+0,0148

+1,63%

Сегодняшний диапазон

0,9150 - 0,9700

ISIN

N/A

Источник

NASDAQ

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

31 июл 2024 15:15:04 Источник Nasdaq GlobeNewswire
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

29 июл 2024 06:02:15 Источник Nasdaq GlobeNewswire
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

25 июл 2024 05:30:20 Источник Nasdaq GlobeNewswire
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

21 июн 2024 06:00:00 Источник Nasdaq GlobeNewswire
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

20 июн 2024 05:30:31 Источник Nasdaq GlobeNewswire
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy

31 май 2024 07:36:49 Источник Nasdaq GlobeNewswire
Ocugen to Present at BIO International Convention 2024

29 май 2024 06:15:00 Источник Nasdaq GlobeNewswire
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

28 май 2024 06:02:39 Источник Nasdaq GlobeNewswire
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

20 май 2024 06:00:52 Источник Nasdaq GlobeNewswire
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

15 май 2024 05:30:00 Источник Nasdaq GlobeNewswire
Ocugen Provides Business Update with First Quarter 2024 Financial Results

14 май 2024 07:00:25 Источник Nasdaq GlobeNewswire
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

10 май 2024 15:05:06 Источник Nasdaq GlobeNewswire
Ocugen to Present at May 2024 Investor Conferences

10 май 2024 06:45:07 Источник Nasdaq GlobeNewswire
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

03 май 2024 06:30:05 Источник Nasdaq GlobeNewswire
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress

02 май 2024 06:15:46 Источник Nasdaq GlobeNewswire
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

29 апр 2024 05:45:00 Источник Nasdaq GlobeNewswire
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

26 апр 2024 08:05:24 Источник Nasdaq GlobeNewswire
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

26 апр 2024 05:30:40 Источник Nasdaq GlobeNewswire
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

19 апр 2024 06:13:05 Источник Nasdaq GlobeNewswire
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

12 апр 2024 06:30:34 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.